Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy
Globoid cell leukodystrophy (GLD) is an autosomal recessive, lysosomal storage disease caused by deficiency of the enzyme galactocerebrosidase (GALC). The absence of GALC activity leads to the accumulation of the toxic substance psychosine and the preferential loss of myelinating cells in the centra...
Gespeichert in:
Veröffentlicht in: | Gene 2015-10, Vol.571 (1), p.81-90 |
---|---|
Hauptverfasser: | , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 90 |
---|---|
container_issue | 1 |
container_start_page | 81 |
container_title | Gene |
container_volume | 571 |
creator | Lin, Dar-Shong Hsiao, Chung-Der Lee, Allan Yueh-Luen Ho, Che-Sheng Liu, Hsuan-Liang Wang, Tuen-Jen Jian, Yuan-Ren Hsu, Jui-Cheng Huang, Zon-Darr Lee, Tsung-Han Chiang, Ming-Fu |
description | Globoid cell leukodystrophy (GLD) is an autosomal recessive, lysosomal storage disease caused by deficiency of the enzyme galactocerebrosidase (GALC). The absence of GALC activity leads to the accumulation of the toxic substance psychosine and the preferential loss of myelinating cells in the central and peripheral nervous systems. Profound demyelination, astrogliosis and axonopathy are the hallmarks of the pathogenesis of GLD, and cerebellar ataxia is one of the dominant manifestations in adolescents and adults affected with GLD. To date, studies regarding cerebellar degeneration in GLD are limited. In this study, the efficacy of cerebellum-targeted gene therapy on the cerebellar neuropathology in twitcher mice (a murine model of GLD) has been validated. We observed degeneration of Purkinje cells, Bergmann glia, and granule cells in addition to astrocytosis and demyelination in the cerebellum of the twitcher mice. Ultrastructural analysis revealed dark cell degeneration and disintegration of the cellular composition of Purkinje cells in untreated twitcher mice. In addition, the expressions of neurotrophic factors CNTF, GDNF and IGF-I were up-regulated and the expression of BDNF was down-regulated. Intracerebellar-mediated gene therapy efficiently corrected enzymatic deficiency by direct transduction to Purkinje cells and cross-correction in other cell types in the cerebellum, leading to the amelioration of both neuroinflammation and demyelination. The population, dendritic territory, and axonal processes of Purkinje cells remained normal in the cerebellum of treated twitcher mice, where radial fibers of Bergmann glia spanned the molecular layer and collateral branches ensheathed the dendritic processes of Purkinje cells. Moreover, the aberrant expressions of neurotrophic factors were mitigated in the cerebellum of treated twitcher mice, indicating the preservation of cellular function in addition to maintaining the neuronal architecture. The life span of the treated twitcher mice was significantly prolonged and their neurobehavioral performance was improved. Taken together, our findings underscore the complexity of cerebellar neurodegeneration in GLD and highlight the potential effectiveness of gene therapy in mitigating neuropathological deficits in GLD and other neurodegenerative disorders in which Purkinje cells are involved.
•Purkinje cell and Bergmann glia degeneration contributes to the pathology of GLD.•GLD mice have aberrant expression of neurotro |
doi_str_mv | 10.1016/j.gene.2015.06.049 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1709164874</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0378111915007593</els_id><sourcerecordid>1709164874</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-f94be751711508aafd4a2713acfc8728312dcbe49b96d010272b7f545cc329653</originalsourceid><addsrcrecordid>eNp9kEFv1DAQhS1URLctf4AD8rGXBNuJ7VjqZVUVqFTEBXq1HHuy9ZKNF9tByr_H0W45Mpc5zDdP7z2EPlBSU0LFp329gwlqRiiviahJq96gDe2kqghpugu0IY3sKkqpukRXKe1JGc7ZO3TJBKVcCrFB7pvPfmeyDxMOA7YQoYdxNBFPMMdwNPllwX7CuzH0wbsCjCMeYf4V3JJyAcr54C3gfsHb7XN1AOdNBodXazi_QDTH5Qa9HcyY4P15X6Ofnx9-3H-tnr5_ebzfPlW25SpXg2p7kJzKYo50xgyuNUzSxtjBdpJ1DWXO9tCqXglHKGGS9XLgLbe2YUrw5hrdnnSPMfyeIWV98Gl1bCYIc9JUEkVF28m2oOyE2hhSijDoY_QHExdNiV7b1Xu9RtBru5oIXdotTx_P-nNfgv57ea2zAHcnAErKPx6iTtbDZEspEWzWLvj_6f8F9CyL7A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1709164874</pqid></control><display><type>article</type><title>Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Lin, Dar-Shong ; Hsiao, Chung-Der ; Lee, Allan Yueh-Luen ; Ho, Che-Sheng ; Liu, Hsuan-Liang ; Wang, Tuen-Jen ; Jian, Yuan-Ren ; Hsu, Jui-Cheng ; Huang, Zon-Darr ; Lee, Tsung-Han ; Chiang, Ming-Fu</creator><creatorcontrib>Lin, Dar-Shong ; Hsiao, Chung-Der ; Lee, Allan Yueh-Luen ; Ho, Che-Sheng ; Liu, Hsuan-Liang ; Wang, Tuen-Jen ; Jian, Yuan-Ren ; Hsu, Jui-Cheng ; Huang, Zon-Darr ; Lee, Tsung-Han ; Chiang, Ming-Fu</creatorcontrib><description>Globoid cell leukodystrophy (GLD) is an autosomal recessive, lysosomal storage disease caused by deficiency of the enzyme galactocerebrosidase (GALC). The absence of GALC activity leads to the accumulation of the toxic substance psychosine and the preferential loss of myelinating cells in the central and peripheral nervous systems. Profound demyelination, astrogliosis and axonopathy are the hallmarks of the pathogenesis of GLD, and cerebellar ataxia is one of the dominant manifestations in adolescents and adults affected with GLD. To date, studies regarding cerebellar degeneration in GLD are limited. In this study, the efficacy of cerebellum-targeted gene therapy on the cerebellar neuropathology in twitcher mice (a murine model of GLD) has been validated. We observed degeneration of Purkinje cells, Bergmann glia, and granule cells in addition to astrocytosis and demyelination in the cerebellum of the twitcher mice. Ultrastructural analysis revealed dark cell degeneration and disintegration of the cellular composition of Purkinje cells in untreated twitcher mice. In addition, the expressions of neurotrophic factors CNTF, GDNF and IGF-I were up-regulated and the expression of BDNF was down-regulated. Intracerebellar-mediated gene therapy efficiently corrected enzymatic deficiency by direct transduction to Purkinje cells and cross-correction in other cell types in the cerebellum, leading to the amelioration of both neuroinflammation and demyelination. The population, dendritic territory, and axonal processes of Purkinje cells remained normal in the cerebellum of treated twitcher mice, where radial fibers of Bergmann glia spanned the molecular layer and collateral branches ensheathed the dendritic processes of Purkinje cells. Moreover, the aberrant expressions of neurotrophic factors were mitigated in the cerebellum of treated twitcher mice, indicating the preservation of cellular function in addition to maintaining the neuronal architecture. The life span of the treated twitcher mice was significantly prolonged and their neurobehavioral performance was improved. Taken together, our findings underscore the complexity of cerebellar neurodegeneration in GLD and highlight the potential effectiveness of gene therapy in mitigating neuropathological deficits in GLD and other neurodegenerative disorders in which Purkinje cells are involved.
•Purkinje cell and Bergmann glia degeneration contributes to the pathology of GLD.•GLD mice have aberrant expression of neurotrophic factors in the cerebellum.•Gene therapy corrects GALC enzyme deficiency in GLD mice.•Gene therapy ameliorates cerebellar neuropathology in GLD mice.•Gene therapy mitigates motor impairment and prolongs life span of GLD mice.</description><identifier>ISSN: 0378-1119</identifier><identifier>EISSN: 1879-0038</identifier><identifier>DOI: 10.1016/j.gene.2015.06.049</identifier><identifier>PMID: 26115766</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Adeno-associated virus ; Animals ; Brain-Derived Neurotrophic Factor - genetics ; Brain-Derived Neurotrophic Factor - metabolism ; Cerebellar Diseases - genetics ; Cerebellar Diseases - therapy ; Cerebellum - metabolism ; Cerebellum - pathology ; Cerebellum - ultrastructure ; Ciliary Neurotrophic Factor - genetics ; Ciliary Neurotrophic Factor - metabolism ; Dependovirus - genetics ; Galactosylceramidase - genetics ; Galactosylceramidase - metabolism ; Gene Expression ; Genetic Therapy - methods ; Genetic Vectors - administration & dosage ; Genetic Vectors - genetics ; Glial Cell Line-Derived Neurotrophic Factor - genetics ; Glial Cell Line-Derived Neurotrophic Factor - metabolism ; Gliosis - genetics ; Gliosis - metabolism ; Globoid cell leukodystrophy ; Immunohistochemistry ; Insulin-Like Growth Factor I - genetics ; Insulin-Like Growth Factor I - metabolism ; Kaplan-Meier Estimate ; Leukodystrophy, Globoid Cell - genetics ; Leukodystrophy, Globoid Cell - therapy ; Lysosomal storage disease ; Mice, Inbred C57BL ; Mice, Neurologic Mutants ; Microscopy, Electron, Transmission ; Neuroglia - metabolism ; Neuroglia - pathology ; Neurotrophic factor ; Purkinje cells ; Purkinje Cells - metabolism ; Purkinje Cells - pathology ; Purkinje Cells - ultrastructure ; Reverse Transcriptase Polymerase Chain Reaction</subject><ispartof>Gene, 2015-10, Vol.571 (1), p.81-90</ispartof><rights>2015 Elsevier B.V.</rights><rights>Copyright © 2015 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-f94be751711508aafd4a2713acfc8728312dcbe49b96d010272b7f545cc329653</citedby><cites>FETCH-LOGICAL-c459t-f94be751711508aafd4a2713acfc8728312dcbe49b96d010272b7f545cc329653</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.gene.2015.06.049$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26115766$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lin, Dar-Shong</creatorcontrib><creatorcontrib>Hsiao, Chung-Der</creatorcontrib><creatorcontrib>Lee, Allan Yueh-Luen</creatorcontrib><creatorcontrib>Ho, Che-Sheng</creatorcontrib><creatorcontrib>Liu, Hsuan-Liang</creatorcontrib><creatorcontrib>Wang, Tuen-Jen</creatorcontrib><creatorcontrib>Jian, Yuan-Ren</creatorcontrib><creatorcontrib>Hsu, Jui-Cheng</creatorcontrib><creatorcontrib>Huang, Zon-Darr</creatorcontrib><creatorcontrib>Lee, Tsung-Han</creatorcontrib><creatorcontrib>Chiang, Ming-Fu</creatorcontrib><title>Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy</title><title>Gene</title><addtitle>Gene</addtitle><description>Globoid cell leukodystrophy (GLD) is an autosomal recessive, lysosomal storage disease caused by deficiency of the enzyme galactocerebrosidase (GALC). The absence of GALC activity leads to the accumulation of the toxic substance psychosine and the preferential loss of myelinating cells in the central and peripheral nervous systems. Profound demyelination, astrogliosis and axonopathy are the hallmarks of the pathogenesis of GLD, and cerebellar ataxia is one of the dominant manifestations in adolescents and adults affected with GLD. To date, studies regarding cerebellar degeneration in GLD are limited. In this study, the efficacy of cerebellum-targeted gene therapy on the cerebellar neuropathology in twitcher mice (a murine model of GLD) has been validated. We observed degeneration of Purkinje cells, Bergmann glia, and granule cells in addition to astrocytosis and demyelination in the cerebellum of the twitcher mice. Ultrastructural analysis revealed dark cell degeneration and disintegration of the cellular composition of Purkinje cells in untreated twitcher mice. In addition, the expressions of neurotrophic factors CNTF, GDNF and IGF-I were up-regulated and the expression of BDNF was down-regulated. Intracerebellar-mediated gene therapy efficiently corrected enzymatic deficiency by direct transduction to Purkinje cells and cross-correction in other cell types in the cerebellum, leading to the amelioration of both neuroinflammation and demyelination. The population, dendritic territory, and axonal processes of Purkinje cells remained normal in the cerebellum of treated twitcher mice, where radial fibers of Bergmann glia spanned the molecular layer and collateral branches ensheathed the dendritic processes of Purkinje cells. Moreover, the aberrant expressions of neurotrophic factors were mitigated in the cerebellum of treated twitcher mice, indicating the preservation of cellular function in addition to maintaining the neuronal architecture. The life span of the treated twitcher mice was significantly prolonged and their neurobehavioral performance was improved. Taken together, our findings underscore the complexity of cerebellar neurodegeneration in GLD and highlight the potential effectiveness of gene therapy in mitigating neuropathological deficits in GLD and other neurodegenerative disorders in which Purkinje cells are involved.
•Purkinje cell and Bergmann glia degeneration contributes to the pathology of GLD.•GLD mice have aberrant expression of neurotrophic factors in the cerebellum.•Gene therapy corrects GALC enzyme deficiency in GLD mice.•Gene therapy ameliorates cerebellar neuropathology in GLD mice.•Gene therapy mitigates motor impairment and prolongs life span of GLD mice.</description><subject>Adeno-associated virus</subject><subject>Animals</subject><subject>Brain-Derived Neurotrophic Factor - genetics</subject><subject>Brain-Derived Neurotrophic Factor - metabolism</subject><subject>Cerebellar Diseases - genetics</subject><subject>Cerebellar Diseases - therapy</subject><subject>Cerebellum - metabolism</subject><subject>Cerebellum - pathology</subject><subject>Cerebellum - ultrastructure</subject><subject>Ciliary Neurotrophic Factor - genetics</subject><subject>Ciliary Neurotrophic Factor - metabolism</subject><subject>Dependovirus - genetics</subject><subject>Galactosylceramidase - genetics</subject><subject>Galactosylceramidase - metabolism</subject><subject>Gene Expression</subject><subject>Genetic Therapy - methods</subject><subject>Genetic Vectors - administration & dosage</subject><subject>Genetic Vectors - genetics</subject><subject>Glial Cell Line-Derived Neurotrophic Factor - genetics</subject><subject>Glial Cell Line-Derived Neurotrophic Factor - metabolism</subject><subject>Gliosis - genetics</subject><subject>Gliosis - metabolism</subject><subject>Globoid cell leukodystrophy</subject><subject>Immunohistochemistry</subject><subject>Insulin-Like Growth Factor I - genetics</subject><subject>Insulin-Like Growth Factor I - metabolism</subject><subject>Kaplan-Meier Estimate</subject><subject>Leukodystrophy, Globoid Cell - genetics</subject><subject>Leukodystrophy, Globoid Cell - therapy</subject><subject>Lysosomal storage disease</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Neurologic Mutants</subject><subject>Microscopy, Electron, Transmission</subject><subject>Neuroglia - metabolism</subject><subject>Neuroglia - pathology</subject><subject>Neurotrophic factor</subject><subject>Purkinje cells</subject><subject>Purkinje Cells - metabolism</subject><subject>Purkinje Cells - pathology</subject><subject>Purkinje Cells - ultrastructure</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><issn>0378-1119</issn><issn>1879-0038</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kEFv1DAQhS1URLctf4AD8rGXBNuJ7VjqZVUVqFTEBXq1HHuy9ZKNF9tByr_H0W45Mpc5zDdP7z2EPlBSU0LFp329gwlqRiiviahJq96gDe2kqghpugu0IY3sKkqpukRXKe1JGc7ZO3TJBKVcCrFB7pvPfmeyDxMOA7YQoYdxNBFPMMdwNPllwX7CuzH0wbsCjCMeYf4V3JJyAcr54C3gfsHb7XN1AOdNBodXazi_QDTH5Qa9HcyY4P15X6Ofnx9-3H-tnr5_ebzfPlW25SpXg2p7kJzKYo50xgyuNUzSxtjBdpJ1DWXO9tCqXglHKGGS9XLgLbe2YUrw5hrdnnSPMfyeIWV98Gl1bCYIc9JUEkVF28m2oOyE2hhSijDoY_QHExdNiV7b1Xu9RtBru5oIXdotTx_P-nNfgv57ea2zAHcnAErKPx6iTtbDZEspEWzWLvj_6f8F9CyL7A</recordid><startdate>20151015</startdate><enddate>20151015</enddate><creator>Lin, Dar-Shong</creator><creator>Hsiao, Chung-Der</creator><creator>Lee, Allan Yueh-Luen</creator><creator>Ho, Che-Sheng</creator><creator>Liu, Hsuan-Liang</creator><creator>Wang, Tuen-Jen</creator><creator>Jian, Yuan-Ren</creator><creator>Hsu, Jui-Cheng</creator><creator>Huang, Zon-Darr</creator><creator>Lee, Tsung-Han</creator><creator>Chiang, Ming-Fu</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20151015</creationdate><title>Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy</title><author>Lin, Dar-Shong ; Hsiao, Chung-Der ; Lee, Allan Yueh-Luen ; Ho, Che-Sheng ; Liu, Hsuan-Liang ; Wang, Tuen-Jen ; Jian, Yuan-Ren ; Hsu, Jui-Cheng ; Huang, Zon-Darr ; Lee, Tsung-Han ; Chiang, Ming-Fu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-f94be751711508aafd4a2713acfc8728312dcbe49b96d010272b7f545cc329653</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adeno-associated virus</topic><topic>Animals</topic><topic>Brain-Derived Neurotrophic Factor - genetics</topic><topic>Brain-Derived Neurotrophic Factor - metabolism</topic><topic>Cerebellar Diseases - genetics</topic><topic>Cerebellar Diseases - therapy</topic><topic>Cerebellum - metabolism</topic><topic>Cerebellum - pathology</topic><topic>Cerebellum - ultrastructure</topic><topic>Ciliary Neurotrophic Factor - genetics</topic><topic>Ciliary Neurotrophic Factor - metabolism</topic><topic>Dependovirus - genetics</topic><topic>Galactosylceramidase - genetics</topic><topic>Galactosylceramidase - metabolism</topic><topic>Gene Expression</topic><topic>Genetic Therapy - methods</topic><topic>Genetic Vectors - administration & dosage</topic><topic>Genetic Vectors - genetics</topic><topic>Glial Cell Line-Derived Neurotrophic Factor - genetics</topic><topic>Glial Cell Line-Derived Neurotrophic Factor - metabolism</topic><topic>Gliosis - genetics</topic><topic>Gliosis - metabolism</topic><topic>Globoid cell leukodystrophy</topic><topic>Immunohistochemistry</topic><topic>Insulin-Like Growth Factor I - genetics</topic><topic>Insulin-Like Growth Factor I - metabolism</topic><topic>Kaplan-Meier Estimate</topic><topic>Leukodystrophy, Globoid Cell - genetics</topic><topic>Leukodystrophy, Globoid Cell - therapy</topic><topic>Lysosomal storage disease</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Neurologic Mutants</topic><topic>Microscopy, Electron, Transmission</topic><topic>Neuroglia - metabolism</topic><topic>Neuroglia - pathology</topic><topic>Neurotrophic factor</topic><topic>Purkinje cells</topic><topic>Purkinje Cells - metabolism</topic><topic>Purkinje Cells - pathology</topic><topic>Purkinje Cells - ultrastructure</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lin, Dar-Shong</creatorcontrib><creatorcontrib>Hsiao, Chung-Der</creatorcontrib><creatorcontrib>Lee, Allan Yueh-Luen</creatorcontrib><creatorcontrib>Ho, Che-Sheng</creatorcontrib><creatorcontrib>Liu, Hsuan-Liang</creatorcontrib><creatorcontrib>Wang, Tuen-Jen</creatorcontrib><creatorcontrib>Jian, Yuan-Ren</creatorcontrib><creatorcontrib>Hsu, Jui-Cheng</creatorcontrib><creatorcontrib>Huang, Zon-Darr</creatorcontrib><creatorcontrib>Lee, Tsung-Han</creatorcontrib><creatorcontrib>Chiang, Ming-Fu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Gene</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lin, Dar-Shong</au><au>Hsiao, Chung-Der</au><au>Lee, Allan Yueh-Luen</au><au>Ho, Che-Sheng</au><au>Liu, Hsuan-Liang</au><au>Wang, Tuen-Jen</au><au>Jian, Yuan-Ren</au><au>Hsu, Jui-Cheng</au><au>Huang, Zon-Darr</au><au>Lee, Tsung-Han</au><au>Chiang, Ming-Fu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy</atitle><jtitle>Gene</jtitle><addtitle>Gene</addtitle><date>2015-10-15</date><risdate>2015</risdate><volume>571</volume><issue>1</issue><spage>81</spage><epage>90</epage><pages>81-90</pages><issn>0378-1119</issn><eissn>1879-0038</eissn><abstract>Globoid cell leukodystrophy (GLD) is an autosomal recessive, lysosomal storage disease caused by deficiency of the enzyme galactocerebrosidase (GALC). The absence of GALC activity leads to the accumulation of the toxic substance psychosine and the preferential loss of myelinating cells in the central and peripheral nervous systems. Profound demyelination, astrogliosis and axonopathy are the hallmarks of the pathogenesis of GLD, and cerebellar ataxia is one of the dominant manifestations in adolescents and adults affected with GLD. To date, studies regarding cerebellar degeneration in GLD are limited. In this study, the efficacy of cerebellum-targeted gene therapy on the cerebellar neuropathology in twitcher mice (a murine model of GLD) has been validated. We observed degeneration of Purkinje cells, Bergmann glia, and granule cells in addition to astrocytosis and demyelination in the cerebellum of the twitcher mice. Ultrastructural analysis revealed dark cell degeneration and disintegration of the cellular composition of Purkinje cells in untreated twitcher mice. In addition, the expressions of neurotrophic factors CNTF, GDNF and IGF-I were up-regulated and the expression of BDNF was down-regulated. Intracerebellar-mediated gene therapy efficiently corrected enzymatic deficiency by direct transduction to Purkinje cells and cross-correction in other cell types in the cerebellum, leading to the amelioration of both neuroinflammation and demyelination. The population, dendritic territory, and axonal processes of Purkinje cells remained normal in the cerebellum of treated twitcher mice, where radial fibers of Bergmann glia spanned the molecular layer and collateral branches ensheathed the dendritic processes of Purkinje cells. Moreover, the aberrant expressions of neurotrophic factors were mitigated in the cerebellum of treated twitcher mice, indicating the preservation of cellular function in addition to maintaining the neuronal architecture. The life span of the treated twitcher mice was significantly prolonged and their neurobehavioral performance was improved. Taken together, our findings underscore the complexity of cerebellar neurodegeneration in GLD and highlight the potential effectiveness of gene therapy in mitigating neuropathological deficits in GLD and other neurodegenerative disorders in which Purkinje cells are involved.
•Purkinje cell and Bergmann glia degeneration contributes to the pathology of GLD.•GLD mice have aberrant expression of neurotrophic factors in the cerebellum.•Gene therapy corrects GALC enzyme deficiency in GLD mice.•Gene therapy ameliorates cerebellar neuropathology in GLD mice.•Gene therapy mitigates motor impairment and prolongs life span of GLD mice.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>26115766</pmid><doi>10.1016/j.gene.2015.06.049</doi><tpages>10</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0378-1119 |
ispartof | Gene, 2015-10, Vol.571 (1), p.81-90 |
issn | 0378-1119 1879-0038 |
language | eng |
recordid | cdi_proquest_miscellaneous_1709164874 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Adeno-associated virus Animals Brain-Derived Neurotrophic Factor - genetics Brain-Derived Neurotrophic Factor - metabolism Cerebellar Diseases - genetics Cerebellar Diseases - therapy Cerebellum - metabolism Cerebellum - pathology Cerebellum - ultrastructure Ciliary Neurotrophic Factor - genetics Ciliary Neurotrophic Factor - metabolism Dependovirus - genetics Galactosylceramidase - genetics Galactosylceramidase - metabolism Gene Expression Genetic Therapy - methods Genetic Vectors - administration & dosage Genetic Vectors - genetics Glial Cell Line-Derived Neurotrophic Factor - genetics Glial Cell Line-Derived Neurotrophic Factor - metabolism Gliosis - genetics Gliosis - metabolism Globoid cell leukodystrophy Immunohistochemistry Insulin-Like Growth Factor I - genetics Insulin-Like Growth Factor I - metabolism Kaplan-Meier Estimate Leukodystrophy, Globoid Cell - genetics Leukodystrophy, Globoid Cell - therapy Lysosomal storage disease Mice, Inbred C57BL Mice, Neurologic Mutants Microscopy, Electron, Transmission Neuroglia - metabolism Neuroglia - pathology Neurotrophic factor Purkinje cells Purkinje Cells - metabolism Purkinje Cells - pathology Purkinje Cells - ultrastructure Reverse Transcriptase Polymerase Chain Reaction |
title | Mitigation of cerebellar neuropathy in globoid cell leukodystrophy mice by AAV-mediated gene therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A25%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitigation%20of%20cerebellar%20neuropathy%20in%20globoid%20cell%20leukodystrophy%20mice%20by%20AAV-mediated%20gene%20therapy&rft.jtitle=Gene&rft.au=Lin,%20Dar-Shong&rft.date=2015-10-15&rft.volume=571&rft.issue=1&rft.spage=81&rft.epage=90&rft.pages=81-90&rft.issn=0378-1119&rft.eissn=1879-0038&rft_id=info:doi/10.1016/j.gene.2015.06.049&rft_dat=%3Cproquest_cross%3E1709164874%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1709164874&rft_id=info:pmid/26115766&rft_els_id=S0378111915007593&rfr_iscdi=true |